A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients with Progressive or Symptomatic Epithelioid Hemangioendothelioma.
Detailed Description: Avoid duplicating information that will be entered or uploaded elsewhere in the record.
Renal function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN).
Nitrosoureas (e.g., carmustine, lomustine) or mitomycin C: within 6 weeks prior to the first dose of study drug;
Oral fluoropyrimidines and small-molecule targeted agents: within 2 weeks prior to the first dose of study drug or within 5 known half-lives of the drug, whichever is longer;
Traditional Chinese medicines with anti-tumor indications: within 2 weeks prior to the first dose of study drug.
Received any other unapproved investigational product within 4 weeks prior to the first dose of study drug.